RxDoctor Payments Data

Kimberly Bethel, MD

Internal Medicine · Trotwood, OHNPI 1215982574

Payments from drug & device makers

$9,622in general payments, 2019–2025

Across 126 payments — averaging $76.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Research Institute, Inc.$5K
  • Novo Nordisk$1K
  • Johnson & Johnson$854
  • Abbott$774
  • AbbVie$424
  • Dexcom, Inc.$359
  • plus $992 from 14 others

What the payments were for

  • Food & beverage$4,501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,622 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$36,805
Medicare patients
120
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide198$203,040
JardianceEmpagliflozin184$153,777
TrulicityDulaglutide134$136,296
MounjaroTirzepatide69$75,930
KerendiaFinerenone95$72,255
EliquisApixaban103$65,894
XareltoRivaroxaban71$64,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,930
LinzessLinaclotide36$26,114
FarxigaDapagliflozin Propanediol44$25,331
JanuviaSitagliptin Phosphate25$22,551
Tresiba Flextouch U-200Insulin Degludec23$17,168
Breo ElliptaFluticasone/Vilanterol26$16,394
MyrbetriqMirabegron14$14,204
TrintellixVortioxetine Hydrobromide11$13,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$36$212,226203 claims
Novo NordiskOzempic$1,097$203,040198 claims
Boehringer IngelheimJardiance$112$153,777184 claims
BayerKerendia$167$72,25595 claims
PfizerEliquis$19$65,894103 claims
Johnson & JohnsonXarelto$854$64,06971 claims
GSKTrelegy Ellipta, Breo Ellipta$34$45,32461 claims
AstraZenecaFarxiga, Symbicort$55$33,01578 claims
AbbVieLinzess$424$26,11436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Trotwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →